Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | GPCR family 3 C terminal | 0.026 | 0.0438 | 0.0001 |
Echinococcus multilocularis | GPCR, family 3, C terminal | 0.026 | 0.0438 | 0.0001 |
Loa Loa (eye worm) | hypothetical protein | 0.041 | 0.1279 | 0.088 |
Echinococcus granulosus | metabotropic glutamate receptor 2 | 0.1341 | 0.648 | 0.632 |
Schistosoma mansoni | lipoxygenase | 0.026 | 0.0437 | 0.0477 |
Schistosoma mansoni | metabotropic glutamate receptor | 0.1341 | 0.648 | 0.7076 |
Loa Loa (eye worm) | glutamate receptor | 0.16 | 0.7932 | 0.7838 |
Loa Loa (eye worm) | receptor family ligand binding region containing protein | 0.041 | 0.1279 | 0.088 |
Schistosoma mansoni | metabotropic glutamate receptor | 0.078 | 0.3346 | 0.3654 |
Schistosoma mansoni | hypothetical protein | 0.026 | 0.0438 | 0.0478 |
Echinococcus multilocularis | metabotropic glutamate receptor 5 | 0.197 | 1 | 1 |
Brugia malayi | metabotropic glutamate receptor subtype 5a (mGluR5a), putative | 0.145 | 0.7091 | 0.8878 |
Loa Loa (eye worm) | glutamate receptor | 0.063 | 0.2505 | 0.2162 |
Schistosoma mansoni | metabotropic glutamate receptor 2 3 (mglur group 2) | 0.182 | 0.9159 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.197 | 1 | 1 |
Onchocerca volvulus | Metabotropic glutamate receptor homolog | 0.026 | 0.0438 | 0.5 |
Brugia malayi | Metabotropic glutamate receptor precursor. | 0.16 | 0.7932 | 1 |
Echinococcus multilocularis | metabotropic glutamate receptor 2 | 0.1341 | 0.648 | 0.632 |
Loa Loa (eye worm) | metabotropic GABA-B receptor subtype 2 | 0.041 | 0.1279 | 0.088 |
Onchocerca volvulus | Poor gastrulation protein homolog | 0.026 | 0.0438 | 0.5 |
Brugia malayi | Receptor family ligand binding region containing protein | 0.041 | 0.1279 | 0.1122 |
Brugia malayi | metabotropic glutamate receptor type 2 | 0.078 | 0.3346 | 0.3881 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | 25456391 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.